A first in-human study of A166 in patients with locally advanced/metastatic solid tumors which are HER2-positive or HER2-amplified who did not respond or stopped responding to approved therapies.Yongheng Liu, Jingyi Wang, Qing Yan et al.|Journal of Clinical Oncology|2020Cited by 50
SKB264 ADC: A first-in-human study of SKB264 in patients with locally advanced unresectable/metastatic solid tumors who are refractory to available standard therapies.Yongheng Liu, Jingyi Wang, Wei Lian et al.|Journal of Clinical Oncology|2020Cited by 21
A phase I study of safety and pharmacokinetics of A166, a novel selective inhibitor of human epidermal growth factor receptor-2 in Chinese patients with advanced solid tumors.Yongheng Liu, Jingyi Wang, Tongtong Xue et al.|Journal of Clinical Oncology|2020Cited by 3